Nina Senutovitch, PhD

Postdoctoral Associate, Dept. of Computational and Systems Biology & Drug Discovery Institute

Nina Senutovitch, PhD

Office: W908 BST
Phone: 412-624-1238

PhD in Biological Sciences, Carnegie Mellon University

My scientific interests include the detection of real-time changes in molecular and cellular events over long time periods with the aim of reporting biological cell signaling mechanisms within living cells.

My overall research interests include improving the ability to monitor specific molecular mechanisms cells utilize in health and disease processes, such that early disease processes and toxicity can be detected and quantified. Specifically, I harness fluorescent protein biosensors to detail intracellular molecular events and signaling phenomena occurring within human microphysiological systems. Biosensors are critical components of a novel all-human liver microphysiological system, also referred to as a “tissue chip” developed by our group to detect early human cellular toxicities and pathologies.

The model has the ability to improve drug development, drug screening efforts and disease characterization.

During my post-doctoral training in the Taylor Lab I have assisted in the development of a novel human liver microchip liver model for drug safety,drug efficacy and disease models. During my training career I have successfully developed novel fluorescent technologies as well as miniature human organ models for use in toxicity studies and disease models.

My research focus is in the application of Quantitative Systems Pharmacology (QSP) to develop more effective drug discovery strategies that utilize integrated computational and phenotype/function-based analysis. In particular, I am leading the Huntington’s Disease QSP program where we are aligning transcriptomic data with chemogenomic data to infer critical molecular pathways involved in the disease progression and in the protection of neurotoxicity by small molecule drugs. I am also involved in the development of an iPSC-based platform for neuronal protection against infectious diseases. Finally, my research interests extend to developing approaches to detect and quantify heterogeneity in cell based model systems.

  1. Hutson M. Shane, Alexander Peter G., Allwardt Vanessa, Aronoff David M., Bruner-Tran Kaylon L., Cliffel David E., Davidson Jeffrey M., Gough Albert, Markov Dmitry A., McCawley Lisa J., McKenzie Jennifer R., McLean John A., Osteen Kevin G., Pensabene Virginia, Samson Philip C., Senutovitch Nina K., Sherrod Stacy D., Shotwell Matthew S., Taylor D. Lansing, Tetz Lauren M., Tuan Rocky S., Vernetti Lawrence A., and Wikswo John P. “Organs-on-Chips as Bridges for Predictive Toxicology (2016).” Appl In Vitro Tox. 2(2): 97-102.
  2. Vernetti LA*, Senutovitch N*, Boltz R, DeBiasio R, Shun TY, Gough A, Taylor DL.“A human liver microphysiology platform for investigating physiology, drug safety, and disease models (2016).” Exp Biol Med (Maywood). 241(1):101-14. *co-authorship
  3. Senutovitch N*, Vernetti L*, Boltz R, DeBiasio R, Gough A, Taylor DL. “Fluorescent protein biosensors applied to microphysiological systems (2015).” Exp Biol Med (Maywood). 240(6):795-808. *co-authorship
  4. Bale SS, Vernetti L, Senutovitch N, Jindal R, Hegde M, Gough A, McCarty WJ, Bakan A, Bhushan A, Shun TY, Golberg I, DeBiasio R, Usta OB, Taylor DL, Yarmush ML. “In vitro platforms for evaluating liver toxicity (2014).” Exp Biol Med (Maywood). 239(9):1180-91.
  5. Bhushan A, Senutovitch N, Bale SS, McCarty WJ, Hegde M, Jindal R, Golberg I, Berk Usta O, Yarmush ML, Vernetti L, Gough A, Bakan A, Shun TY, DeBiasio R, Lansing Taylor D. “Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans (2013).” Stem Cell Res Ther. 2013;4 Suppl 1:S16.